Investigating the link between certain blood mutations and sudden cardiac death risk

Clonal Hematopoeisis of Indeterminate Potential and Risk of Autopsy-defined Sudden Cardiac Death

['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10995306

This study is looking at how certain blood cell mutations, known as clonal hematopoiesis of indeterminate potential (CHIP), might raise the risk of serious heart problems, including sudden cardiac death, by examining genetic changes in patients who have passed away.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded)
Locations1 site (SAN FRANCISCO, UNITED STATES)
Trial IDNIH-10995306 on ClinicalTrials.gov

What this research studies

This research focuses on clonal hematopoiesis of indeterminate potential (CHIP), a condition where specific blood cell mutations may increase the risk of serious cardiovascular events, including sudden cardiac death. By analyzing genetic mutations in blood cells and their association with sudden cardiac death, the study aims to understand how these mutations contribute to heart disease and mortality. The research utilizes a large cohort of patients who have undergone autopsy to accurately determine the causes of sudden cardiac death, providing a comprehensive view of the relationship between CHIP and cardiovascular health.

Who could benefit from this research

Good fit: Ideal candidates for this research include adults with identified mutations associated with clonal hematopoiesis and those at risk for cardiovascular diseases.

Not a fit: Patients without the relevant blood mutations or those who do not have cardiovascular risk factors may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved risk assessment and preventive strategies for individuals with specific blood mutations, potentially reducing the incidence of sudden cardiac death.

How similar studies have performed: Previous research has shown a significant association between CHIP mutations and increased cardiovascular risks, indicating that this approach is based on established findings.

Where this research is happening

SAN FRANCISCO, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: atherosclerotic coronary disease

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.